Type I Interferon-mediated Stimulation of T Cells by CpG DNA
Overview
General Medicine
Affiliations
Immunostimulatory DNA and oligodeoxynucleotides containing unmethylated CpG motifs (CpG DNA) are strongly stimulatory for B cells and antigen-presenting cells (APCs). We report here that, as manifested by CD69 and B7-2 upregulation, CpG DNA also induces partial activation of T cells, including naive-phenotype T cells, both in vivo and in vitro. Under in vitro conditions, CpG DNA caused activation of T cells in spleen cell suspensions but failed to stimulate highly purified T cells unless these cells were supplemented with APCs. Three lines of evidence suggested that APC-dependent stimulation of T cells by CpG DNA was mediated by type I interferons (IFN-I). First, T cell activation by CpG DNA was undetectable in IFN-IR-/- mice. Second, in contrast to normal T cells, the failure of purified IFN-IR-/- T cells to respond to CpG DNA could not be overcome by adding normal IFN-IR+ APCs. Third, IFN-I (but not IFN-gamma) caused the same pattern of partial T cell activation as CpG DNA. Significantly, T cell activation by IFN-I was APC independent. Thus, CpG DNA appeared to stimulate T cells by inducing APCs to synthesize IFN-I, which then acted directly on T cells via IFN-IR. Functional studies suggested that activation of T cells by IFN-I was inhibitory. Thus, exposing normal (but not IFN-IR-/-) T cells to CpG DNA in vivo led to reduced T proliferative responses after TCR ligation in vitro.
Drobek A, Bernaleau L, Delacretaz M, Calderon Copete S, Royer-Chardon C, Longepierre M Nat Commun. 2025; 16(1):967.
PMID: 39856058 PMC: 11759703. DOI: 10.1038/s41467-024-55692-y.
Control of adaptive immunity by pattern recognition receptors.
Carroll S, Pasare C, Barton G Immunity. 2024; 57(4):632-648.
PMID: 38599163 PMC: 11037560. DOI: 10.1016/j.immuni.2024.03.014.
Liu Y, Zhai G, Fu W, Zhang X, Xu J Front Pharmacol. 2022; 13:1063106.
PMID: 36578554 PMC: 9790930. DOI: 10.3389/fphar.2022.1063106.
Cytosolic dsRNA improves neonatal innate immune responses to adjuvants in use in pediatric vaccines.
Brennan K, Craven S, Cheung M, Kane D, Noone E, OCallaghan J J Leukoc Biol. 2022; 112(3):523-537.
PMID: 35098572 PMC: 9542317. DOI: 10.1002/JLB.5A0521-242R.
Haabeth O, Lohmeyer J, Sallets A, Blake T, Sagiv-Barfi I, Czerwinski D ACS Cent Sci. 2021; 7(7):1191-1204.
PMID: 34341771 PMC: 8265720. DOI: 10.1021/acscentsci.1c00361.